Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTalha BadarOJOmer JamyYWYu‐Hung Wang

Discussion

Loading...

Member takes

Overview

Observational study highlights differences in clinical outcomes between azacitidine and decitabine in TP53-mutant acute myeloid leukemia, suggesting implications for treatment strategy.

Key Points

  • This research aims to compare the effectiveness of azacitidine and decitabine in TP53-mutant acute myeloid leukemia.
  • Conducted a multicenter observational study in 15 U.S. academic centers.
  • Reviewed electronic medical records of 652 TP53-mutant AML patients.
  • Analyzed patient outcomes after receiving either azacitidine or decitabine, with propensity score matching to reduce bias.
  • Complete remission rates were 35% for azacitidine versus 49.7% for decitabine (p=0.02).
  • Overall survival and event-free survival were comparable between the two treatment groups.
  • Adding venetoclax negatively impacted outcomes for overall survival in the propensity matched cohort.

Cite This Study

Badar et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d05ehttps://doi.org/10.1182/blood-2025-874
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy2025
  2. 2Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.2025
  3. 3IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  4. 4Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia2026
  5. 5Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion2025 · 1 citations